Sydnexis v. Eyenovia: Federal Circuit Affirms Unpatentability of Ophthalmic Composition Patent
Sydnexis, Inc. appealed a patentability ruling covering US10888557B2, an ophthalmic composition patent, against rival Eyenovia, Inc. The Federal Circuit affirmed the finding of unpatentability after 600 days of proceedings, extinguishing Sydnexis’s patent rights in this formulation space.
Federal Circuit Ends Sydnexis’s Ophthalmic Patent After 600-Day Appeal
Sydnexis, Inc. filed this appeal at the U.S. Court of Appeals for the Federal Circuit on 20 September 2023, challenging an earlier finding that US10888557B2 — its patent covering an ophthalmic composition — was unpatentable. The opposing party, Eyenovia, Inc., a competing ophthalmic drug delivery company, successfully defended the invalidity determination below. The patent in suit, filed under application number US16/785413, sits at the intersection of pharmaceutical formulation and ocular therapeutics, a commercially significant space for topical eye drop and micro-dosing technologies.
The Federal Circuit closed the case on 12 May 2025 with a one-word appellate disposition: AFFIRMED. Under Federal Circuit appellate standards, affirmance means the court found no reversible legal or factual error in the lower tribunal’s unpatentability determination. For Sydnexis, this terminates patent protection for the claimed ophthalmic composition via this route; for Eyenovia, it confirms freedom from infringement liability and removes a potential enforcement barrier in the ophthalmic drug delivery market.
The 600-day duration from filing to disposition is notable — longer than typical Federal Circuit patent appeals, suggesting the case may have involved substantive briefing on claim construction or prior art scope rather than a straightforward procedural resolution. The public record does not disclose the precise prior art basis or the specific claims adjudicated, leaving open questions about the breadth of invalidity and whether Sydnexis retains any related patent family members that could be asserted separately.
Filing to Unpatentable in 600 days
600-day appeal — longer than the median Federal Circuit patent appeal (~450 days)
Federal Circuit affirms: what the unpatentability ruling means for both parties
What ‘AFFIRMED’ means at the Federal Circuit level
An affirmance by the Federal Circuit means the appellate panel reviewed the lower tribunal’s unpatentability determination and found no reversible error — whether legal, procedural, or factual. The standard of review for underlying fact findings (such as obviousness or anticipation) is deferential, typically requiring clear error to overturn. The lower ruling therefore stands in full legal force, and US10888557B2 is conclusively unpatentable through this proceeding.
No reversible error foundSydnexis loses patent protection for this ophthalmic formulation
The affirmance is a definitive adverse outcome for Sydnexis. US10888557B2 has been found unpatentable and the Federal Circuit’s ruling forecloses further appeal at this level. Sydnexis cannot enforce this patent against Eyenovia or any other party. Any commercial exclusivity Sydnexis sought through this patent in the ophthalmic composition space is extinguished, unless related continuation or divisional applications with different claim scope survive separately.
Patent rights extinguishedEyenovia secures confirmed freedom from this patent claim
For Eyenovia, the Federal Circuit’s affirmance provides strong commercial certainty. The unpatentability finding is now final at the appellate level, meaning Eyenovia’s ophthalmic products are not encumbered by US10888557B2. The ruling also raises the bar for any future assertion of the same patent family claims against Eyenovia, as prior adjudication of unpatentability is a powerful estoppel consideration in subsequent proceedings.
Freedom from infringement confirmedOphthalmic formulation space opens as Sydnexis patent falls
This outcome is commercially significant for the ophthalmic drug delivery sector. With US10888557B2 invalidated and affirmed as unpatentable, competitors beyond Eyenovia may gain freedom to operate in the formulation space the patent once covered. Companies developing topical ophthalmic compositions or micro-dosing delivery systems should reassess their FTO positions in light of this ruling. The decision also signals that Federal Circuit review in this technology area is willing to uphold rigorous patentability scrutiny.
Broader competitor freedom likelyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Sydnexis, Inc. | Company | Ophthalmic therapeutics company — holder of US10888557B2 ophthalmic composition patentSearch in Eureka ↗ |
| Defendant | Eyenovia, Inc. | Company | Eyenovia, Inc. — ophthalmic micro-dosing drug delivery company, appeal respondentSearch in Eureka ↗ |
| Plaintiff counsel | Michael T. Rosato | Attorney | Counsel for Sydnexis, Inc.Search in Eureka ↗ |
| Plaintiff law firm | WilsonSonsini Goodrich & Rosati LLP | Law Firm | Representing Sydnexis, Inc.Search in Eureka ↗ |
| Defendant counsel | Williams Dixon | Attorney | Counsel for Eyenovia, Inc.Search in Eureka ↗ |
| Defendant law firm | Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC | Law Firm | Representing Eyenovia, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The single-word verdict ‘AFFIRMED’ carries significant legal weight at the Federal Circuit level. The appellate panel reviewed the tribunal’s unpatentability determination under the applicable standard of review — deferential for factual findings (clear error) and de novo for legal questions. Affirmance signals the court found no basis to disturb the underlying ruling, meaning the invalidity determination is now final and binding. Neither party can re-litigate the unpatentability of US10888557B2 on these grounds.
US10888557B2 — Ophthalmic Composition Drug Delivery Patent
US10888557B2, filed under application number US16/785413, protects an ophthalmic composition — a formulation designed for topical or ocular administration. Ophthalmic composition patents typically cover the specific combination of active pharmaceutical ingredients, excipients, concentration ranges, pH buffers, and delivery vehicle characteristics that define a proprietary eye drop or ocular solution. Such patents are commercially critical in the ophthalmic therapeutics sector, where formulation differentiation drives market exclusivity independently of the active molecule.
The strategic importance of US10888557B2 lies in its capacity to block or restrict competitors — such as Eyenovia, a micro-dosing ophthalmic delivery specialist — from marketing substantially similar ocular compositions. The Federal Circuit’s affirmance of unpatentability removes this barrier entirely. For the broader ophthalmic drug delivery sector, where pipeline products frequently rely on formulation exclusivity after primary molecule patents expire, this ruling is a reminder that composition claims require robust prosecution and clear differentiation from prior art to survive inter partes or appellate scrutiny.
Should your team run an FTO analysis against US10888557B2?
Any company developing ophthalmic composition products — including topical eye drops, ocular solutions, or micro-dosing delivery systems — that may overlap with the formulation space defined by US10888557B2 should consider a targeted freedom-to-operate review. Although the Federal Circuit has affirmed unpatentability, patent families can include continuation or divisional applications with distinct claim sets. Product and regulatory teams should not assume this single ruling eliminates all related IP risk without a full family search.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map the full patent family around US16/785413, identify any surviving related applications, and benchmark claim scope against your product formulation. Automated prior art mapping and claim comparison tools help teams prioritise FTO risk quickly — critical in a sector where formulation patents can revive enforcement exposure even after a lead patent is invalidated.
Run a freedom-to-operate analysis on US10888557B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit Appeals Involving Ophthalmic and Pharma Formulation Patents
Explore Federal Circuit cases involving ophthalmic and pharmaceutical composition patent invalidity challenges, comparable to Sydnexis v. Eyenovia Case 23-2403.
What this case signals for the ophthalmic drug delivery IP landscape
The Federal Circuit’s affirmance sets a clear precedent signal for formulation patent holders and challengers operating in the ophthalmic therapeutics space.
Ophthalmic formulation patents face heightened invalidity risk at the Federal Circuit
This affirmance confirms the Federal Circuit’s willingness to uphold unpatentability findings in pharmaceutical formulation disputes. Companies holding composition-of-matter patents in ophthalmic drug delivery should audit claim scope and prosecution history for potential obviousness vulnerabilities before asserting or licensing.
Eyenovia’s successful defense clears commercial runway in micro-dosing ophthalmic tech
With US10888557B2 affirmed as unpatentable, Eyenovia operates without this patent overhead. Competing firms developing similar ophthalmic compositions should monitor whether Sydnexis has continuation applications in prosecution that could revive coverage under different claim structures.
Sydnexis v Eyenovia — key questions answered
The Federal Circuit affirmed the unpatentability of Sydnexis’s US10888557B2 ophthalmic composition patent on 12 May 2025. The affirmance means the lower tribunal’s finding of unpatentability was upheld with no reversible error identified, extinguishing Sydnexis’s patent rights in this formulation.
The patent at issue is US10888557B2, filed under application number US16/785413. It covers an ophthalmic composition — a formulation for topical or ocular drug delivery. Such patents typically protect specific combinations of active ingredients, excipients, and delivery vehicle parameters used in eye drop or ocular solution products.
The affirmance confirms that US10888557B2 is unpatentable, meaning Eyenovia faces no infringement liability from this patent. The ruling provides strong commercial certainty for Eyenovia’s ophthalmic products. However, companies should monitor whether Sydnexis holds related continuation or divisional applications with different claim scope that could present residual risk.
The appeal ran for approximately 600 days, from filing on 20 September 2023 to closure on 12 May 2025. This duration is longer than the median Federal Circuit patent appeal and may suggest substantive merits briefing on claim construction, prior art scope, or patentability standards rather than a procedural resolution.
US10888557B2 is conclusively unpatentable following the Federal Circuit’s affirmance and cannot be enforced. Sydnexis may, however, hold related continuation or divisional patents in the same family (under US16/785413) with distinct claim sets that were not subject to this proceeding. A full patent family analysis would be required to assess any residual enforcement capability.
PatSnap Eureka searches patents and litigation data to answer instantly.